MARKET

RNLX

RNLX

Renalytix AI plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

32.00
+0.01
+0.03%
Closed 16:05 06/22 EDT
OPEN
31.80
PREV CLOSE
31.99
HIGH
32.00
LOW
30.56
VOLUME
75.74K
TURNOVER
--
52 WEEK HIGH
35.71
52 WEEK LOW
9.91
MARKET CAP
1.13B
P/E (TTM)
-108.4011
1D
5D
1M
3M
1Y
5Y
Renalytix AI Q3 EPS $(0.12) Beats $(0.15) Estimate, Sales $619.00K Beat $610.00K Estimate
Renalytix AI (NASDAQ:RNLX) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. The company reported quarterly sales of $619.00 thousand which beat the
Benzinga · 06/15 11:17
Renalytix AI EPS beats by $0.06, misses on revenue
Renalytix AI (RNLX): FQ3 GAAP EPS of -$0.12 beats by $0.06.Revenue of $0.62M misses by $0.13M.Shares +0.79% PM.Press Release
Seekingalpha · 06/15 11:10
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2021
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today reported financial results for the quarter and nine months ended March 31, 2021. Recent Highlights Partnership announced with Unive...
GlobeNewswire · 06/15 11:00
Renalytix Posts Wider Fiscal Q3 Loss
MT Newswires · 06/15 07:40
Renalytix to Report Financial Results for Fiscal Third Quarter 2021 and Provide Corporate Update
Announces Change of Auditor to Ernst & Young LLPNEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced the Company will release fiscal third quarter 2021 financial results on Tuesday, June 15, 2021, before m...
GlobeNewswire · 06/10 12:00
Leadership Additions Announced to Support Expanding US Government and Healthcare Provider KidneyIntelX Deployment
Enabling expertise in sales, population health and value-driven care modelsNEW YORK and SALT LAKE CITY, June 07, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced a series of key hires to drive its commercialization strat...
GlobeNewswire · 06/07 11:00
Utility Study Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care
Clinicians affirm need for accurate early-stage diabetic kidney disease risk assessment to improve patient outcomes and reduce healthcare costsNEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced results f...
GlobeNewswire · 06/03 11:00
Bio-Techne and Kantaro Biosciences get Health Canada authorization for COVID-19 test kit
Mount Sinai Health System and RenalytixAI ([[RNLX]] -3.2%) joint venture Kantaro Biosciences and Bio-Techne ([[TECH]] -0.9%) have received Health Canada authorization for COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test kit.COVID-SeroKlir...
Seekingalpha · 06/02 15:52
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RNLX. Analyze the recent business situations of Renalytix AI plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS
Institutional Holdings
Institutions: 39
Institutional Holdings: 6.04M
% Owned: 17.14%
Shares Outstanding: 35.21M
TypeInstitutionsShares
Increased
7
766.18K
New
21
676.98K
Decreased
7
322.47K
Sold Out
3
34.37K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About RNLX
Renalytix AI plc is an artificial intelligence-enabled in vitro diagnostics company. The Company’s diagnostic platform, KidneyIntelX, employs artificial intelligence-enabled algorithm that combines data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record (HER) systems, to generate a patient risk score. Its patient risk score enables prediction of progressive kidney function decline in chronic kidney disease (CKD), allowing physicians and healthcare systems to manage the allocation of treatments and clinical resources to patients. KidneyIntelX provides a reportable patient risk score integrated with specific guideline-driven clinical recommendations designed to manage patient treatment and compliance outcomes. The KidneyIntelX risk score is tied to specific clinical guideline recommendations developed by the healthcare system, health insurance providers or practice groups.

Webull offers kinds of Renalytix AI PLC (ADR) stock information, including NASDAQ:RNLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNLX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RNLX stock methods without spending real money on the virtual paper trading platform.